STOCK TITAN

Xilio Therapeutics (XLO) S-3 Filings

XLO NASDAQ

Here are the S-3 shelf registrations from Xilio Therapeutics, Inc. (XLO) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.

An S-3 covers the shelf registration that lets an established company sell over time, so if you follow XLO and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full XLO filings page.

Rhea-AI Summary

Xilio Therapeutics, Inc. filed Amendment No. 1 to its shelf registration (Form S-3/A) to update the registration following subsequent sales under a prior shelf and to refresh exhibits. The registration statement provides a base shelf permitting up to $250,000,000 of securities and a sales agreement prospectus for up to $14,500,000 of common stock to be sold under an at-the-market agreement with Leerink Partners LLC.

The amendment discloses that the company issued and sold $4,596,248 of securities under a prior S-3 (File No. 333-285703), updates the filing fee table, revises the public float calculation and prospectus exhibits (legal opinion and auditor consent), and supplies the base prospectus text describing possible securities, plan of distribution, and risk factors. The filing states a public float of $57,598,009 based on 6,575,139 shares outstanding as of May 26, 2026, and includes referenced prices of $8.35 (May 26, 2026 last sale) and $8.81 (price used for a prior calculation).

Rhea-AI Summary

Xilio Therapeutics, Inc. has filed a shelf registration to offer up to $250,000,000 of securities, which may include common stock, preferred stock, debt securities, units and warrants. The filing also includes a sales agreement prospectus permitting the issuance and sale of up to $17,220,000 of common stock under an at-the-market sales agreement with Leerink Partners LLC. The prospectus states the net proceeds will be used for general corporate purposes, including research and development and clinical trials, and that specific terms for each offering will be provided in prospectus supplements. The prospectus discloses 5,982,839 shares outstanding as of May 7, 2026 and a public float of $51,666,386 as of May 11, 2026, and reports a last reported sale price of common stock of $7.73 per share on May 11, 2026.